| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM (NCT01816230) | Gamida Cell ltd | 2013-04-01 |
| Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (NCT01758042) | Massachusetts General Hospital | 2012-11-01 |
| AML-MDS Novel Prognostic Tests Clinical Study (NCT01685619) | Nova Scotia Health Authority | 2012-10-02 |
| A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients (NCT01613976) | Novartis Pharmaceuticals | 2012-08-01 |
| Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia (NCT01629082) | National Heart, Lung, and Blood Institute (NHLBI) | 2012-06-06 |
| Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler (NCT01463410) | Skyline Diagnostics BV | 2011-10-01 |
| Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS (NCT01442714) | Stanford University | 2011-08-01 |
| Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia (NCT01373515) | Mendus | 2011-04-01 |
| Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation (NCT01237808) | University of Ulm | 2011-03-01 |
| Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine (NCT01180322) | University of Ulm | 2010-11-01 |
| Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) (NCT01242774) | Novartis Pharmaceuticals | 2010-10-01 |
| Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project (NCT01252485) | University of Ulm | 2010-07-06 |
| Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) (NCT01147939) | Clavis Pharma | 2010-06-01 |
| Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML (NCT00606723) | Hannover Medical School | 2010-04-01 |
| Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia (NCT01034592) | Jason Robert Gotlib | 2009-11-01 |
| Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) (NCT00850382) | University of Ulm | 2009-06-01 |
| Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) (NCT00890929) | Stanford University | 2009-04-01 |
| Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age (NCT00893373) | Technische Universität Dresden | 2009-03-01 |
| Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies (NCT00710528) | Gilead Sciences | 2008-06-01 |
| Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) (NCT00656617) | M.D. Anderson Cancer Center | 2008-04-01 |
| Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine (NCT00655395) | Viron Therapeutics Inc | 2008-03-01 |
| Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML (NCT00568633) | Stanford University | 2007-08-01 |
| Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia (NCT00664677) | Erimos Pharmaceuticals | 2007-08-01 |
| Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers (NCT00488592) | National Heart, Lung, and Blood Institute (NHLBI) | 2007-06-01 |
| Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy (NCT00433745) | National Heart, Lung, and Blood Institute (NHLBI) | 2007-02-01 |
| Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia (NCT00401739) | CSL Limited | 2006-12-01 |
| Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation (NCT00363467) | H. Lee Moffitt Cancer Center and Research Institute | 2006-05-01 |
| Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission (NCT00834002) | University Hospital, Antwerp | 2005-03-01 |
| PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00093600) | Novartis Pharmaceuticals | 2004-02-01 |
| AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) (NCT00071006) | Pfizer | 2003-09-01 |
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies (NCT00145613) | St. Jude Children's Research Hospital | 2003-06-01 |
| The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma (NCT06659224) | asmaa salama ibrahim | 2000-01-01 |
| Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) (NCT03070093) | Astellas Pharma Global Development, Inc. | |
| Expanded Access to Venetoclax (NCT03123029) | AbbVie | |